- Home
- IAF vs CLLS Comparison
IAF vs CLLS Comparison
Compare IAF & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAF
- CLLS
- Stock Information
- Founded
- IAF 1985
- CLLS 1999
- Country
- IAF United States
- CLLS France
- Employees
- IAF N/A
- CLLS N/A
- Industry
- IAF Finance/Investors Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- IAF Finance
- CLLS Health Care
- Exchange
- IAF Nasdaq
- CLLS Nasdaq
- Market Cap
- IAF 123.8M
- CLLS 143.4M
- IPO Year
- IAF N/A
- CLLS 2007
- Fundamental
- Price
- IAF $4.51
- CLLS $1.65
- Analyst Decision
- IAF
- CLLS Buy
- Analyst Count
- IAF 0
- CLLS 1
- Target Price
- IAF N/A
- CLLS $4.00
- AVG Volume (30 Days)
- IAF 90.4K
- CLLS 52.9K
- Earning Date
- IAF 01-01-0001
- CLLS 08-05-2025
- Dividend Yield
- IAF 11.44%
- CLLS N/A
- EPS Growth
- IAF N/A
- CLLS N/A
- EPS
- IAF N/A
- CLLS N/A
- Revenue
- IAF N/A
- CLLS $54,747,000.00
- Revenue This Year
- IAF N/A
- CLLS $48.52
- Revenue Next Year
- IAF N/A
- CLLS $5.17
- P/E Ratio
- IAF N/A
- CLLS N/A
- Revenue Growth
- IAF N/A
- CLLS 351.26
- 52 Week Low
- IAF $3.60
- CLLS $1.10
- 52 Week High
- IAF $4.59
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- IAF 60.35
- CLLS 66.75
- Support Level
- IAF $4.41
- CLLS $1.41
- Resistance Level
- IAF $4.53
- CLLS $1.49
- Average True Range (ATR)
- IAF 0.07
- CLLS 0.10
- MACD
- IAF -0.00
- CLLS 0.02
- Stochastic Oscillator
- IAF 86.11
- CLLS 98.45
About IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.